Skip to content

PT-141

Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.

Intelligence Profile

Clinical Applications

PT-141 (bremelanotide) has been primarily investigated as a treatment for female sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD) in premenopausal women.

Primary Clinical Application

The main clinical use for PT-141 is treating hypoactive sexual desire disorder in premenopausal women. This condition is characterized by persistently low sexual desire that causes distress. Three completed clinical trials have evaluated PT-141's efficacy and safety for this indication:

  • Two Phase 3 trials (NCT02338960 and NCT02333071) specifically examined PT-141's effectiveness and safety in premenopausal women with HSDD
  • One Phase 2 trial (NCT01382719) investigated PT-141 in premenopausal women with both female sexual arousal disorder and/or HSDD

Broader Clinical Context

Recent systematic reviews have positioned PT-141 among emerging pharmacological therapies for female sexual dysfunction. The compound appears in analyses of treatments for hypoactive sexual desire disorder, suggesting it has gained recognition as a viable therapeutic option in this area.

Potential Applications Under Investigation

While the primary evidence focuses on female sexual dysfunction, there is emerging interest in PT-141's potential applications in other areas:

  • Male sexual dysfunction: Recent literature has examined whether bremelanotide should be considered for treating sexual arousal and desire disorders in men
  • Post-cancer sexual health: PT-141 is being discussed as a potential strategy for addressing sexual health concerns in women after breast and gynecologic cancer treatment

Limitations of Current Evidence

The available clinical trial data is primarily focused on premenopausal women with specific sexual dysfunction disorders. Evidence for other populations or conditions appears limited based on the current literature. More research would be needed to establish efficacy and safety in broader clinical applications.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider for personalized treatment recommendations.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.